Core Viewpoint - Investors often prefer stocks with a low price-to-earnings (P/E) ratio, believing that a lower P/E indicates higher stock value and potential for growth [1][2] Group 1: P/E Ratio Insights - Stocks with a rising P/E ratio can also yield strong returns, indicating that as earnings rise, stock prices should follow suit [2][3] - A rising P/E ratio suggests investor confidence in a company's fundamentals and expected future earnings growth [4] - Historical data shows that stocks can experience P/E ratio increases of over 100% from their breakout points, presenting significant investment opportunities if identified early [5] Group 2: Stock Screening Criteria - The screening parameters for identifying stocks with increasing P/E include: - Current year EPS growth estimate should be greater than or equal to last year's actual growth [7] - Price changes over four weeks should exceed those over 12 weeks, and similarly for 12 weeks over 24 weeks, indicating consistent price increases [7][8] - Price change for 12 weeks should be at least 20% higher than for 24 weeks but not exceed 100%, signaling potential uptrends without overvaluation [8] Group 3: Selected Stocks - Four stocks identified with a Zacks Rank of 2 (Buy) include: - **Context Therapeutics (CNTX)**: Focuses on women's oncology with an average four-quarter earnings surprise of 22.37% [9][10] - **Blue Bird (BLBD)**: Engaged in school bus manufacturing with an average four-quarter earnings surprise of 49.64% [10] - **Dycom Industries (DY)**: A specialty contractor in the telecom sector with an average four-quarter earnings surprise of 26.99% [10] - **Leidos (LDOS)**: A leader in science and technology serving various markets, with an average four-quarter earnings surprise of 28.34% [11]

Core Insights - Context Therapeutics Inc. is advancing T cell engaging bispecific antibodies for solid tumors, with a focus on their clinical asset CT-95, which targets mesothelin [1][5] - The company will present data on the first-in-human dose of CT-95 at the AACR Annual Meeting 2025, highlighting the safety of the proposed starting dose of 0.1 μg/kg [2][3] Company Overview - Context Therapeutics is a clinical-stage biopharmaceutical company headquartered in Philadelphia, specializing in T cell engaging bispecific antibodies [5] - The company is developing a portfolio of TCE therapeutics, including CTIM-76, CT-95, and CT-202, targeting various cancer types [5] Product Details - CT-95 is designed to redirect T-cell-mediated lysis towards malignant cells expressing mesothelin, which is overexpressed in approximately 30% of cancers [4] - The product aims to overcome challenges posed by soluble mesothelin fragments that can interfere with MSLN-targeted therapies [4]

CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, March 20, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2024, and rep ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-40654 CONTEXT THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 86-3738787 (State of other jurisdiction of incorporation or organization) (I.R.S. ...

PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 46,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context. The stock option awards were granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance ...

PHILADELPHIA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in the following investor conferences: B. Riley Securities Precision Oncology & Radiopharma Conference: Panel discussions on Friday, February 28, 2025, at 8:00 a.m. and 10:00 a.m. ET in New York, NY.TD Cowen 45th Annual Healthcare Conference: Presentation on Monday, March 3, ...

Clinical Trial Progress - The first patient has been dosed in the Phase 1 clinical trial for CTIM-76, marking a significant milestone in the company's clinical pipeline [1][6] - The Phase 1 trial is an open-label, dose escalation and expansion study evaluating CTIM-76 in patients with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers [4][6] - The trial aims to assess safety, tolerability, pharmacokinetics, and anti-tumor activity, with up to 70 patients expected to be enrolled [4][6] - Initial data from the CTIM-76 Phase 1 trial is anticipated to be shared in the first half of 2026 [6] CTIM-76 Overview - CTIM-76 is a Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody targeting CLDN6-positive cancers [1][6][7] - CLDN6 is enriched in various solid tumors, including ovarian, endometrial, lung, gastric, and testicular cancers [7] - Preclinical research suggests CTIM-76 has potential for convenient dosing, low immunogenicity risk, and scalable manufacturing [7] Company Background - Context Therapeutics Inc is a biopharmaceutical company focused on developing T cell engaging (TCE) bispecific antibodies for solid tumors [2] - The company's pipeline includes CTIM-76, CT-95 (Mesothelin x CD3 bispecific antibody), and CT-202 (Nectin-4 x CD3 bispecific antibody) [2] - Context Therapeutics is headquartered in Philadelphia and is publicly traded on Nasdaq under the ticker CNTX [2]

Core Insights - Context Therapeutics Inc. has appointed Andy Pasternak as the new Chairman of its Board of Directors, succeeding Richard Berman, effective January 12, 2025, marking a significant transition in leadership to guide the company into its next growth phase [1][3] Company Overview - Context Therapeutics is a biopharmaceutical company focused on advancing T cell engaging bispecific antibodies for solid tumors, with a portfolio that includes CTIM-76, CT-95, and CT-202 [4] Leadership Experience - Andy Pasternak brings over 25 years of experience in the biopharmaceutical industry, previously serving as Executive Vice President and Chief Strategy Officer at Horizon Therapeutics, where he played a key role in the $28 billion acquisition by Amgen in 2023 [2] - Pasternak's background includes significant roles at Bain & Company, where he was Head of the Healthcare Practice in the Americas, and he currently serves on the Board of Directors of Endo, Inc. [2] Strategic Vision - Pasternak expressed his commitment to leveraging his experience to help Context continue to innovate in the rapidly evolving field of T cell engagers, aiming to improve patient outcomes [2]

Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody Strengthens board with appointments of Dr. Karen Smith and Dr. Luke Walker Cash and cash equivalents of $84.8 million as of September 30, 2024 PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 10-Q ___________________________________ (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-40654 CONTEXT THERAPEUTICS ...